RSP SYSTEMS A/S

Their core work

RSP Systems is a Danish medical device SME entirely focused on developing GlucoBeam — a portable, pain-free device that measures blood glucose levels in diabetic patients without any skin puncture. Their core technology is Raman spectroscopy, an optical technique that reads glucose concentration through the skin using near-infrared light. The company went from feasibility study to full-scale product development within two years, progressing through both phases of the EU SME Instrument program. Their entire H2020 footprint is a single, coherent product commercialization journey targeting the global diabetes self-monitoring market.

What they specialise in

How they've shifted over time

RSP Systems' H2020 history is not an evolution of topics — it is a single product moving through development stages. The 2016 SME-1 project was a low-budget feasibility study (€50,000) with no detailed keywords, typical of early-stage concept validation. The 2017 SME-2 project, funded at nearly €2.35 million, reveals the full technical depth: Raman spectroscopy applied to non-invasive glucose measurement in diabetic patients. The trajectory shows a company that defined its mission early and stayed disciplined in executing it through to a mature development phase.

RSP Systems is on a focused commercialization path for a single medical device; any future collaboration they seek will almost certainly be about clinical validation, regulatory clearance, or manufacturing scale-up for GlucoBeam.

How they like to work

RSP Systems operated as a solo applicant on both EU projects, using the SME Instrument scheme which is designed for individual companies rather than multi-partner consortia. They led both projects as coordinator with zero recorded consortium partners, indicating they prefer or require tight internal control over their IP-sensitive technology development. Working with them likely means a bilateral arrangement rather than a large research consortium.

RSP Systems has no recorded H2020 consortium partners and collaborated with organizations in zero other countries. Their EU project work was entirely self-contained, with no third parties or subcontractors captured in the CORDIS data.

What sets them apart

RSP Systems is one of the few European SMEs with demonstrated, EU-funded R&D specifically in Raman spectroscopy applied to continuous or on-demand non-invasive glucose measurement — a technically difficult problem that large MedTech companies have tried and failed to commercialize. Their completion of the full SME Instrument cycle (Phase 1 + Phase 2) shows they cleared EU due diligence at both feasibility and commercialization stages. For a consortium needing optical biosensing or diabetes-tech expertise from a specialized Danish innovator, they are a rare and specific asset.

Highlights from their portfolio

• GlucoBeam (SME-2)
  The largest and most substantive project (€2.35M, 2017–2021) represents the full commercial development phase of their non-invasive glucose monitor, making it the clearest evidence of their technical and commercialization capabilities.
• GlucoBeam (SME-1)
  The 2016 Phase 1 feasibility grant demonstrates that GlucoBeam passed independent EU evaluation before scale-up funding was awarded, validating the concept's scientific and market credibility.